Company Profile
Alpine Immune Sciences Stock Price, News & Analysis
- Ticker:
- ALPN
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for ALPN.
Company overview
Business overview
Alpine Immune Sciences was an immunology company focused on protein engineering and immune-modulating biologics before being acquired by Vertex. Its platform was built around engineered immune therapies.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ before acquisition, Alpine sat in specialty biotechnology.
Business Model Characteristics
The business depended on platform engineering, clinical data, and the strategic value of its immune-modulation pipeline.
Position Within the Biotechnology Landscape
Alpine was a differentiated immunology platform name and now belongs to biotech M&A history.
Future catalysts
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Alpine Immune Sciences do?
Alpine Immune Sciences was an immunology company focused on protein engineering and immune-modulating biologics before being acquired by Vertex. Its platform was built around engineered immune therapies.
On which exchange is ALPN stock listed?
Alpine Immune Sciences (ALPN) is associated with NASDAQ, United States, Biopharma.
What is Alpine?
Alpine Immune Sciences was an immunology company focused on protein engineering and immune-modulating biologics before being acquired by Vertex.
Which conditions is Alpine Immune Sciences targeting with Alpine?
Alpine Immune Sciences is associated with immunology based on its company overview and current catalyst commentary.
What is Immune?
Alpine Immune Sciences was an immunology company focused on protein engineering and immune-modulating biologics before being acquired by Vertex.
What is Sciences?
Alpine Immune Sciences was an immunology company focused on protein engineering and immune-modulating biologics before being acquired by Vertex.